Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study

Mohany,Khalid M.; Al Rugaie,Osamah; Al‑Wutayd,Osama; Alsharidah,Mansour; Al‑Nafeesah,Abdullah

doi:10.3892/etm.2022.11330

Circulating miR‑15b, Annexin A1, procalcitonin and interleukin‑6 levels differentiate children with metabolically unhealthy obesity from those with metabolically healthy obesity: A case‑control study

Authors:
- Khalid M. Mohany
- Osamah Al Rugaie
- Osama Al‑Wutayd
- Mansour Alsharidah
- Abdullah Al‑Nafeesah
View Affiliations

Affiliations: Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt, Department of Basic Medical Sciences, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Kingdom of Saudi Arabia, Department of Family and Community Medicine, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Kingdom of Saudi Arabia, Department of Physiology, College of Medicine, Qassim University, Buraydah 51452, Kingdom of Saudi Arabia, Department of Pediatrics, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah 51911, Kingdom of Saudi Arabia
Published online on: April 21, 2022 https://doi.org/10.3892/etm.2022.11330
Article Number: 403
Copyright: © Mohany et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study assessed serum miR‑15b, Annexin A1, procalcitonin, and interleukin‑6 (IL‑6) levels in children with metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) and compared them to these levels in a non‑obese healthy control group. It also tested the ability of each of these parameters to early differentiate children with MUO from those with MHO. The present study included 620 children [434 males (70%) and 186 females (30%); aged 9‑15 years] divided into the following groups: G1, healthy non‑obese controls (n=200); G2, MHO (n=246); G3, MUO (n=174). Serum miR‑15b, Annexin A1 procalcitonin, IL‑6, and other metabolic parameters levels were measured, and clinical examinations were conducted for all of the children. After testing the normality of the variable, Kruskal‑Wallis one‑way‑ANOVA, and Spearman correlation coefficients were used. The area under the receiver operating characteristic curve (AUC) was determined to test the variable's ability to differentiate MUO from MHO. miR‑15b, procalcitonin, and IL‑6 levels were significantly higher while Annexin A1 levels were significantly lower in G2 and G3 when compared to G1, and in G3 when compared to G2. These levels were positively correlated (Annexin A1 was negatively correlated) with body mass index (BMI) and waist circumference percentiles, and with serum levels of LDL‑cholesterol, glucose, HbA1c, insulin, and C‑reactive protein (CRP) and with the homeostasis model of insulin resistance (HOMA‑IR). The AUC was 0.92, 0.84, 0.82, and 0.67 for miR‑15b, Annexin A1, procalcitonin, and IL‑6, respectively. In conclusion, determination of serum miR‑15b, Annexin A1, and procalcitonin levels could differentiate children with MUO from those with MHO. This may help the early management of these cases and their accompanying complications.

View Figures

View References

1	World Health Organization: Report of the commission on ending childhood obesity. Implementation plan: Executive summary. Geneva: World Health Organization, 2017.
2	Al Dhaifallah A, Mwanri L and Aljoudi A: Childhood obesity in Saudi Arabia: Opportunities and challenge. Saudi J Obesity. 3:2–7. 2015.
3	Cui X, You L, Zhu L, Wang X, Zhou Y, Li Y, Wen J, Xia Y, Wang X, Ji C and Guo X: Change in circulating microRNA profile of obese children indicates future risk of adult diabetes. Metab Clin Exp. 78:95–105. 2018.PubMed/NCBI View Article : Google Scholar
4	Mohany KM, Al Rugaie O, Al-wutayd O, Al-Nafeesah A and Saleem TH: Association between circulating microRNAs 486, 146b and 15b and serum betatrophin levels in obese; type 2 diabetic and non-diabetic children. BMC Endocr Disord. 20(145)2020.PubMed/NCBI View Article : Google Scholar
5	Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB and Schulze MB: Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 Year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 6:714–724. 2018.PubMed/NCBI View Article : Google Scholar
6	Blüher M: Metabolically healthy obesity. Endocr Rev. 41(bnaa004)2020.PubMed/NCBI View Article : Google Scholar
7	Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K and Nirantharakumar K: Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 70:1429–1437. 2017.PubMed/NCBI View Article : Google Scholar
8	Ellulu MS, Patimah I, Khaza'ai H, Rahmat A and Abed Y: Obesity and inflammation: The linking mechanism and the complications. Arch Med Sci. 13:851–863. 2017.PubMed/NCBI View Article : Google Scholar
9	Iacomino G and Siani A: Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 12(23)2017.PubMed/NCBI View Article : Google Scholar
10	Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martínez JA and Marti A: Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 29:3595–3611. 2015.PubMed/NCBI View Article : Google Scholar
11	Yang WM, Jeong HJ, Park SW and Lee W: Obesity-induced miR-15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes. Mol Nutr Food Res. 59:2303–2314. 2015.PubMed/NCBI View Article : Google Scholar
12	Zhong H, Ma M, Liang T and Guo L: Role of MicroRNAs in obesity-induced metabolic disorder and immune response. J Immunol Res. 2018(2835761)2018.PubMed/NCBI View Article : Google Scholar
13	Sugimoto MA, Vago JP, Teixeira MM and Sousa LP: Annexin A1 and the resolution of inflammation: Modulation of neutrophil recruitment, apoptosis, and clearance. J Immunol Res. 2016(8239258)2016.PubMed/NCBI View Article : Google Scholar
14	Pietrani NT, Ferreira CN, Rodrigues KF, Perucci LO, Carneiro FS, Bosco AA, Oliveira MC, Pereira SS, Teixeira AL, Alvarez-Leite JI, et al: Proresolving protein Annexin A1: The role in type 2 diabetes mellitus and obesity. Biomed Pharmacother. 103:482–489. 2018.PubMed/NCBI View Article : Google Scholar
15	Aguilera CM, Gomez-Llorente C, Tofe I, Gil-Campos M, Cañete R and Gil Á: Genome-wide expression in visceral adipose tissue from obese prepubertal children. Int J Mol Sci. 16:7723–7737. 2015.PubMed/NCBI View Article : Google Scholar
16	Kosicka A, Cunliffe AD, Mackenzie R, Zariwala MG, Perretti M, Flower RJ and Renshaw D: Attenuation of plasma Annexin A1 in human obesity. FASEB J. 27:368–378. 2013.PubMed/NCBI View Article : Google Scholar
17	Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G and Bakker SJ: Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab. 95:E26–E31. 2010.PubMed/NCBI View Article : Google Scholar
18	El Kassas GM, Shehata MA, El Wakeel MA, Amer AF, Elzaree FA, Darwish MK and Amer MF: Role of procalcitonin as an inflammatory marker in a sample of Egyptian children with simple obesity. Open Access Maced J Med Sci. 6:1349–1353. 2018.PubMed/NCBI View Article : Google Scholar
19	Khaodhiar L, Ling PR, Blackburn GL and Bistrian BR: Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J Parenter Enteral Nutr. 28:410–415. 2004.PubMed/NCBI View Article : Google Scholar
20	Takumansang R, Warouw SM and Lestari H: Interleukin-6 and insulin resistance in obese adolescents. Paediatr Indones. 53:268–272. 2013.
21	El-Mikkawy DM, EL-Sadek MA, EL-Badawy MA and Samaha D: Circulating level of interleukin-6 in relation to body mass indices and lipid profile in Egyptian adults with overweight and obesity. Egypt Rheumatol Rehabil. 47(7)2020.
22	Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J and Caprio S: IDF Consensus Group. The metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr Diabetes. 8:299–306. 2007.PubMed/NCBI View Article : Google Scholar
23	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985.PubMed/NCBI View Article : Google Scholar
24	Ivo D'Urso P, Fernando D'Urso O, Damiano Gianfreda C, Mezzolla V, Storelli C and Marsigliante S: miR-15b and miR-21 as circulating biomarkers for diagnosis of glioma. Curr Genomics. 16:304–311. 2015.PubMed/NCBI View Article : Google Scholar
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
26	Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R and Plodkowski R: Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 22 (Suppl 3):S1–S203. 2016.PubMed/NCBI View Article : Google Scholar
27	Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, et al: Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement. Lancet Diabetes Endocrinol. 7:715–725. 2019.PubMed/NCBI View Article : Google Scholar
28	Vukovic R, Dos Santos TJ, Ybarra M and Atar M: Children with metabolically healthy obesity: A review. Front Endocrinol (Lausanne). 10(865)2019.PubMed/NCBI View Article : Google Scholar
29	Li Y and Shi X: MicroRNAs in the regulation of TLR and RIG-I pathways. Cell Mol Immunol. 10:65–71. 2013.PubMed/NCBI View Article : Google Scholar
30	Sajid S, Renshaw D, Burke B and Mee C: Investigating the role of Annexin A1 in adipogenesis and its ability to dampen obesity associated inflammation. Endocr Abstr. 50(335)2017.
31	Becker KL, Snider R and Nylen ES: Procalcitonin in sepsis and systemic inflammation: A harmful biomarker and a therapeutic target. Br J pharmacol. 159:253–264. 2010.PubMed/NCBI View Article : Google Scholar
32	Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Périat P, Bucher HC and Christ-Crain M: Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 168:2000–2008. 2008.PubMed/NCBI View Article : Google Scholar
33	Mehanic S and Baljic R: The importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsis. Mater Sociomed. 25:277–281. 2013.PubMed/NCBI View Article : Google Scholar
34	Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U and Müller B: Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 32:1715–1721. 2004.PubMed/NCBI View Article : Google Scholar
35	Van Gaal LF, Mertens IL and De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature. 444:875–880. 2006.PubMed/NCBI View Article : Google Scholar
36	Ghanem AI and Khalid M: Association of serum procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) levels with insulin resistance and obesity in type 2 Egyptian diabetic patients. Med J Cairo Univ. 84:1165–1171. 2016.
37	Boursier G, Avignon A, Kuster N, Boegner C, Leprieur E, Picandet M, Bargnoux AS, Badiou S, Dupuy AM, Cristol JP and Sultan A: Procalcitonin, an independent marker of abdominal fat accumulation in obese patients. Clin Lab. 62:435–441. 2016.PubMed/NCBI View Article : Google Scholar